[Worsening of epilepsies under treatment].
D000927:Anticonvulsants / Q000009:adverse effects* / Q000627:therapeutic use; D001570:Benzodiazepinones / Q000009:adverse effects* / Q000627:therapeutic use; D002648:Child; D002675:Child, Preschool; D002722:Chlorobenzenes / Q000009:adverse effects / Q000627:therapeutic use; D004359:Drug Therapy, Combination; D004827:Epilepsy / Q000188:drug therapy*; D004832:Epilepsy, Absence / Q000139:chemically induced*; D005069:Evaluation Studies as Topic; D005260:Female; D006801:Humans; D008297:Male; D009574:Nitro Compounds / Q000009:adverse effects / Q000627:therapeutic use; D010634:Phenobarbital / Q000009:adverse effects* / Q000627:therapeutic use; D010672:Phenytoin / Q000009:adverse effects* / Q000627:therapeutic use
D000927:Anticonvulsants; D001570:Benzodiazepinones; D002722:Chlorobenzenes; D009574:Nitro Compounds; D010672:Phenytoin; D010634:Phenobarbital
Agravamento de epilepsias sob tratamento.